Literature DB >> 35648416

A Two-stage Approach for Rapid Assessment of the Proportion Achieving Viral Suppression Using Routine Clinical Data.

Jessie K Edwards1, Yeycy Donastorg2, Sabrina Zadrozny3, Sarah Hileman4, Hoisex Gómez2, Marissa J Seamans5, Michael E Herce6, Edwin Ramírez7, Clare Barrington8, Sharon Weir1,8.   

Abstract

BACKGROUND: Improving viral suppression among people with HIV reduces morbidity, mortality, and transmission. Accordingly, monitoring the proportion of patients with a suppressed viral load is important to optimizing HIV care and treatment programs. But viral load data are often incomplete in clinical records. We illustrate a two-stage approach to estimate the proportion of treated people with HIV who have a suppressed viral load in the Dominican Republic.
METHODS: Routinely collected data on viral load and patient characteristics were recorded in a national database, but 74% of patients on treatment at the time of the study did not have a recent viral load measurement. We recruited a subset of these patients for a rapid assessment that obtained additional viral load measurements. We combined results from the rapid assessment and main database using a two-stage weighting approach and compared results to estimates obtained using standard approaches to account for missing data.
RESULTS: Of patients with recent routinely collected viral load data, 60% had a suppressed viral load. Results were similar after applying standard approaches to account for missing data. Using the two-stage approach, we estimated that 77% (95% confidence interval [CI] = 74, 80) of those on treatment had a suppressed viral load.
CONCLUSIONS: When assessing the proportion of people on treatment with a suppressed viral load using routinely collected data, applying standard approaches to handle missing data may be inadequate. In these settings, augmenting routinely collected data with data collected through sampling-based approaches could allow more accurate and efficient monitoring of HIV treatment program effectiveness.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35648416      PMCID: PMC9378579          DOI: 10.1097/EDE.0000000000001513

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.860


  26 in total

1.  Addressing an idiosyncrasy in estimating survival curves using double sampling in the presence of self-selected right censoring.

Authors:  C E Frangakis; D B Rubin
Journal:  Biometrics       Date:  2001-06       Impact factor: 2.571

2.  HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable.

Authors:  Robert W Eisinger; Carl W Dieffenbach; Anthony S Fauci
Journal:  JAMA       Date:  2019-02-05       Impact factor: 56.272

3.  All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up.

Authors:  Nanina Anderegg; Leigh F Johnson; Elizabeth Zaniewski; Keri N Althoff; Eric Balestre; Matthew Law; Denis Nash; Bryan E Shepherd; Constantin T Yiannoutsos; Matthias Egger
Journal:  AIDS       Date:  2017-04       Impact factor: 4.177

Review 4.  Improving laboratory efficiencies to scale-up HIV viral load testing.

Authors:  George Alemnji; Philip Onyebujoh; John N Nkengasong
Journal:  Curr Opin HIV AIDS       Date:  2017-03       Impact factor: 4.283

5.  Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa.

Authors:  Elvin H Geng; Nneka Emenyonu; Mwebesa Bosco Bwana; David V Glidden; Jeffrey N Martin
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

6.  A longitudinal, HIV care continuum: 10-year restricted mean time in each care continuum stage after enrollment in care, by history of IDU.

Authors:  Catherine R Lesko; Jessie K Edwards; Richard D Moore; Bryan Lau
Journal:  AIDS       Date:  2016-09-10       Impact factor: 4.177

Review 7.  The HIV care cascade: a systematic review of data sources, methodology and comparability.

Authors:  Nicholas A Medland; James H McMahon; Eric P F Chow; Julian H Elliott; Jennifer F Hoy; Christopher K Fairley
Journal:  J Int AIDS Soc       Date:  2015-11-30       Impact factor: 5.396

8.  Status of HIV Epidemic Control Among Adolescent Girls and Young Women Aged 15-24 Years - Seven African Countries, 2015-2017.

Authors:  Kristin Brown; Daniel B Williams; Steve Kinchen; Suzue Saito; Elizabeth Radin; Hetal Patel; Andrea Low; Stephen Delgado; Owen Mugurungi; Godfrey Musuka; Beth A Tippett Barr; E Amaka Nwankwo-Igomu; Leala Ruangtragool; Avi J Hakim; Thokozani Kalua; Rose Nyirenda; Gertrude Chipungu; Andrew Auld; Evelyn Kim; Danielle Payne; Nellie Wadonda-Kabondo; Christine West; Elizabeth Brennan; Beth Deutsch; Anteneh Worku; Sasi Jonnalagadda; Lloyd B Mulenga; Kumbutso Dzekedzeke; Danielle T Barradas; Haotian Cai; Sundeep Gupta; Stanley Kamocha; Margaret A Riggs; Karampreet Sachathep; Wilford Kirungi; Joshua Musinguzi; Alex Opio; Sam Biraro; Elizabeth Bancroft; Jennifer Galbraith; Herbert Kiyingi; Mansoor Farahani; Wolfgang Hladik; Edith Nyangoma; Choice Ginindza; Zandile Masangane; Fortune Mhlanga; Zandile Mnisi; Pasipamire Munyaradzi; Amos Zwane; Sean Burke; Felix B Kayigamba; Harriet Nuwagaba-Biribonwoha; Ruben Sahabo; Trong T Ao; Chiara Draghi; Caroline Ryan; Neena M Philip; Fausta Mosha; Aroldia Mulokozi; Phausta Ntigiti; Angela A Ramadhani; Geoffrey R Somi; Cecilia Makafu; Veronicah Mugisha; Julius Zelothe; Kayla Lavilla; David W Lowrance; Rennatus Mdodo; Elizabeth Gummerson; Paul Stupp; Kyaw Thin; Koen Frederix; Stefania Davia; Amee M Schwitters; Stephen D McCracken; Yen T Duong; David Hoos; Bharat Parekh; Jessica E Justman; Andrew C Voetsch
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-12       Impact factor: 17.586

9.  Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis.

Authors:  Martin W G Brinkhof; Mar Pujades-Rodriguez; Matthias Egger
Journal:  PLoS One       Date:  2009-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.